Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Storia naturale dell'ipertensione portale non cirrotica

Background:

- Noncirrhotic Portal Hypertension (NCPH) is caused by liver diseases that increase pressure in the blood vessels of the liver. It seems to start slowly and not have many warning signs. Many people may not even know that they have a liver disease. There are no specific treatments for NCPH.

Objectives:

- To learn more about how NCPH develops over time.

Eligibility:

- People age 12 and older who have NCPH or are at risk for getting it. In the past year, they cannot have had other types of liver disease that typically result in cirrhosis, liver cancer, or active substance abuse.

Design:

  • Participants will have 2 screening visits.
  • Visit 1: to see if they have or may develop NCPH.
  • Medical history
  • Physical exam
  • Urine and stool studies
  • Abdominal ultrasound
  • Fibroscan. Sound waves measure liver stiffness.

<TAB>- Visit 2:

  • Blood tests
  • Abdominal MRI
  • Echocardiogram
  • Questionnaire
  • Liver blood vessel pressure (hepatic venous portal gradient (HVPG)) measurement. This is done with a small tube inserted in a neck vein.
  • They may have a liver biopsy.
  • All participants will visit the clinic every 6 months for a history, physical exam, and blood tests. They will also repeat some of the screening tests yearly.
  • Participants with NCPH will also have:
  • Upper endoscopy test. A tube inserted in the mouth goes through the esophagus and stomach.
  • At least every 2 years: Esophagogastroduodenoscopy.
  • At least every 4 years: testing including HVPG measurements and liver biopsy.
  • Participants without NCPH will also have:
  • Liver biopsy and HVPG measurements to see if they have NCPH.
  • Every 2 years: abdominal MRI and stool studies.
  • The study will last indefinitely.

Panoramica dello studio

Stato

Reclutamento

Condizioni

Descrizione dettagliata

Study Description:

Up to 400 subjects with noncirrhotic portal hypertension or at risk for developing noncirrhotic portal hypertension by virtue of their

underlying disease (as well as sporadic cases of noncirrhotic portal hypertension as referred to in this protocol) will be offered inclusion

in the study.

Objectives:

Primary Objective:

1. The goal of this natural history study is to generate understanding of the development and progression of NCPH. We will use our

findings to generate novel biomarkers that will enable improved follow-up of patients, assist in preventing complications, and

enhance transplant decision.

Secondary Objectives:

  1. Measurement of the bile acids and lipids to understand NCPH and porto-systemic shunting.
  2. Identification of the genetic modifiers of NCPH.
  3. Evaluation of hepatic transcriptome in absence and presence of NCPH.
  4. Characterization of microbiome signatures in NCPH.

Endpoints:

Primary Endpoints:

  1. Establish surveillance methods and guidelines for evaluation of NCPH.
  2. Develop an understanding of the biological mechanisms of the progression of NCPH.
  3. Identification of novel biomarkers correlating with NCPH progression.

Secondary Endpoints:

  1. Measurement of bile acids fractionated and total, as well as lipid panel to establish cut-off levels correlating with NCPH severity.
  2. Establishment of positive or negative correlation between candidate susceptible genes and disease phenotype.
  3. Identification of novel markers of fibrosis or the development of hepatic neoplasia from transcriptome analysis.
  4. Characterization of microbiome signatures (taxonomic and functional), as well as identification of specific species.

Tipo di studio

Osservativo

Iscrizione (Stimato)

400

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Contatto studio

Backup dei contatti dello studio

Luoghi di studio

    • Maryland
      • Bethesda, Maryland, Stati Uniti, 20892
        • Reclutamento
        • National Institutes of Health Clinical Center
        • Contatto:
        • Contatto:
          • For more information at the NIH Clinical Center contact Office of Patient Recruitment (OPR)
          • Numero di telefono: TTY dial 711 (800) 411-1222
          • Email: ccopr@nih.gov

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

Da 12 anni a 100 anni (Bambino, Adulto, Adulto più anziano)

Accetta volontari sani

No

Sessi ammissibili allo studio

Tutto

Metodo di campionamento

Campione non probabilistico

Popolazione di studio

Subjects with diagnosis of noncirrhotic portal hypertension above age of 12 years

Descrizione

  • INCLUSION CRITERIA:

In order to be eligible to participate in this study, an individual must meet all of the following criteria:

  • Male or female, aged >= 18 years of age, and minors 12-17 years of age.
  • Women of childbearing potential must agree to use birth control unless they are menopausal or had hysterectomy.
  • Known diagnosis of NCPH, or to be at the risk for NCPH by virtue of underlying disease processes such as but not limited to; CGD, SCD, Mastocytosis, CVID, CF, and CHF.

EXCLUSION CRITERIA:

An individual who meets any of the following criteria will be excluded from participation in this study:

  • Pregnancy.
  • Evidence of other forms of liver disease that typically result in cirrhosis.
  • Evidence of active Chronic Hepatitis B infection as defined by the presence of hepatitis B surface antigen (HBsAg) in serum and elevated HBV DNA (>10,000 IU/mL).
  • Hepatitis C as defined by the presence of hepatitis C RNA in serum.
  • Evidence of other liver disease such as primary sclerosing cholangitis, primary biliary cirrhosis, Wilson s disease, autoimmune hepatitis as defined by either liver histology or laboratory abnormalities.
  • Hemochromatosis as defined by presence of 3+ or 4+ stainable iron on liver biopsy or homozygosity for C282Y. Patients with iron saturation indices of >45% and serum ferritin levels of >300 ng/ml for men and >250 ng/ml for women will undergo genetic testing for hemochromatosis.
  • Bile duct obstruction as suggested by imaging studies done within the previous six months.
  • The presence of cirrhosis confirmed by liver biopsy.
  • Active substance abuse, such as alcohol, inhaled or injection drugs within the previous one year (assessed during subject interviews by subject self-report).
  • Evidence of hepatocellular carcinoma; either alpha-fetoprotein (AFP) levels greater than 50 ng/ml (normal <6.6ng/ml) and/or ultrasound (or other imaging study) demonstrating a mass suggestive of liver cancer.
  • Evidence of cholangiocarcinoma as suggested by liver histology.
  • Any other severe condition, which in the opinion of the investigators would impede the patient s participation or compliance in the study.
  • Inability to comply or give written informed consent.

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Modelli osservazionali: COHORT
  • Prospettive temporali: PROSPECTIVE

Coorti e interventi

Gruppo / Coorte
Adult with absence of Portal Hypertension

Confirmed absence of Portal Hypertension will have no findings suggestive of non cirrhotic portal hypertension on liver biopsy and on portal pressure measurements on confirmatory examination.

Adult with presence of Portal Hypertension

Confirmed Presence of Noncirrhotic Portal Hypertension, through confirmatory testing, tissue diagnosis by liver biopsy and/or portal hypertension (HVPG >5mmHg).

Minors likely to have the absence of Portal Hypertension

Minors identified as Confirmed Absence of Noncirrhotic Portal Hypertension will have no abnormal findings on confirmatory examination.

Minors likely to have the presence of Portal Hypertension

Minors identified as Confirmed Presence of Noncirrhotic Portal Hypertension, have shown they have the disease with a tissue diagnosis by liver biopsy and/or portal hypertension (HVPG >5).

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
To study the natural history of non cirrhotic portal hypertension. It is an ongoing study.
Lasso di tempo: Ongoing

natural history study

Ongoing

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Sponsor

Investigatori

  • Investigatore principale: Theo Heller, M.D., National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Pubblicazioni e link utili

La persona responsabile dell'inserimento delle informazioni sullo studio fornisce volontariamente queste pubblicazioni. Questi possono riguardare qualsiasi cosa relativa allo studio.

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Effettivo)

27 luglio 2015

Completamento primario (Stimato)

4 settembre 2029

Completamento dello studio (Stimato)

4 settembre 2029

Date di iscrizione allo studio

Primo inviato

15 aprile 2015

Primo inviato che soddisfa i criteri di controllo qualità

15 aprile 2015

Primo Inserito (Stimato)

16 aprile 2015

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

9 novembre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

6 novembre 2026

Ultimo verificato

4 novembre 2026

Maggiori informazioni

Termini relativi a questo studio

Altri numeri di identificazione dello studio

  • 150108
  • 15-DK-0108

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

INDECISO

Descrizione del piano IPD

This is a longitudinal study and it is not yet known if and when IPD will be made available.

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

No

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .